Stoneridge Investment Partners LLC decreased its position in shares of Omeros Corporation (NASDAQ:OMER) by 2.0% during the third quarter, Holdings Channel reports. The institutional investor owned 121,446 shares of the biopharmaceutical company’s stock after selling 2,455 shares during the period. Stoneridge Investment Partners LLC owned about 0.31% of Omeros Corporation worth $1,355,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of OMER. Ingalls & Snyder LLC bought a new stake in shares of Omeros Corporation during the second quarter worth about $46,441,000. Bank of Montreal Can bought a new stake in shares of Omeros Corporation during the second quarter worth about $17,641,000. Eidelman Virant Capital bought a new stake in shares of Omeros Corporation during the third quarter worth about $1,763,000. State Street Corp boosted its stake in shares of Omeros Corporation by 16.8% in the second quarter. State Street Corp now owns 881,993 shares of the biopharmaceutical company’s stock worth $9,274,000 after buying an additional 126,595 shares during the period. Finally, Chicago Equity Partners LLC bought a new stake in shares of Omeros Corporation during the second quarter worth about $961,000. 52.05% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)

Shares of Omeros Corporation (NASDAQ:OMER) traded up 0.21% during trading on Friday, hitting $9.33. The stock had a trading volume of 277,786 shares. The company’s market cap is $400.40 million. Omeros Corporation has a 12 month low of $7.20 and a 12 month high of $16.80. The stock has a 50 day moving average of $10.96 and a 200 day moving average of $10.78.

Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.06. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $11.64 million. During the same period in the prior year, the firm posted ($0.53) EPS. The business’s revenue for the quarter was up 253.1% on a year-over-year basis. Equities analysts forecast that Omeros Corporation will post ($1.69) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this article can be viewed at http://www.watchlistnews.com/stoneridge-investment-partners-llc-sells-2455-shares-of-omeros-corporation-omer/1060679.html.

OMER has been the topic of several recent analyst reports. Zacks Investment Research cut Omeros Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, October 12th. Wedbush lowered their price target on Omeros Corporation from $56.00 to $47.00 and set an “outperform” rating on the stock in a report on Wednesday, November 16th. Needham & Company LLC lowered their price target on Omeros Corporation from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, November 10th. WBB Securities reaffirmed a “buy” rating and issued a $75.00 price target on shares of Omeros Corporation in a report on Monday, October 17th. Finally, S&P Equity Research raised their price target on Omeros Corporation from $7.65 to $8.63 in a report on Monday, October 17th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Omeros Corporation has a consensus rating of “Buy” and an average price target of $33.23.

In other news, CEO Gregory A. Md Demopulos sold 306,120 shares of the business’s stock in a transaction dated Friday, December 2nd. The stock was sold at an average price of $11.58, for a total value of $3,544,869.60. Following the transaction, the chief executive officer now directly owns 1,801,381 shares in the company, valued at $20,859,991.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Gregory A. Md Demopulos sold 306,124 shares of the business’s stock in a transaction dated Wednesday, December 7th. The shares were sold at an average price of $10.66, for a total value of $3,263,281.84. Following the completion of the transaction, the chief executive officer now owns 1,987,025 shares in the company, valued at $21,181,686.50. The disclosure for this sale can be found here. Company insiders own 13.60% of the company’s stock.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER).

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.